The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape

Abstract excerpt

The incidence of Melanoma, one among the most lethal cancers, is widespread increasing.” Metastatic melanoma has a poor prognosis representing about 90% of skin cancer mortality. The increased knowledge of tumour biology and the greater understanding of the immune system role in anti-tumour response, allowed to develop a more rational approach to systemic therapies. “The discovery of activating BRAF mutations in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Genomics and Diagnostics
• Share to Cutaneous Melanoma Detection and Management
• Share to Melanoma and MAPK Pathways